Wednesday, February 10, 2010, 8:10pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Celldex Therapeutics, Inc. (CLDX)

At 5:00AM SGT: 4.45 USD   0.00 (0.00%)  
 MORE ON CLDX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Celldex Therapeutics, Inc (NGM:CLDX) Delayed quote dataEdit
Last Trade:4.45 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:4.45
Open:N/A
Bid:2.79 x 10400
Ask:4.79 x 500
1y Target Est:12.00
Day's Range:N/A - N/A
52wk Range:4.16 - 14.19
Volume:0
Avg Vol (3m):317,811
Market Cap:140.63M
P/E (ttm):N/A
EPS (ttm):-1.96
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add CLDX to Portfolio   Download Data

 HEADLINES 
•CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 26)
•CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Sat, Jan 9)
•CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of
EDGAR Online (Fri, Jan 1)
•Mentor Capital Cancer Vaccine Investing Update
at Seeking Alpha (Thu, Dec 24)
•Mentor Capital Plans 2010 Launch of Cancer Vaccine Active Index Fund
at Seeking Alpha (Tue, Dec 22)
•[$$] Small-Caps Push Higher
at The Wall Street Journal Online (Tue, Dec 15)
•Clarient, Celldex: Early Volume Plays
at TheStreet.com (Mon, Dec 14)
•Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
Business Wire (Sun, Dec 13)
•Celldex Therapeutics to Present CDX-011 Clinical Data at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire (Tue, Dec 8)
•CELLDEX THERAPEUTICS, INC. Financials
EDGAR Online Financials (Wed, Nov 11)
•CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
•CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
EDGAR Online (Wed, Nov 4)
More Headlines for CLDX...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.63
EPS Est (in 2 years) (Dec-10) :-1.22
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices